CZD 3.13% 9.3¢ calzada limited

Ann: AOD9604 Positive in Osteoarthritis Animal Mo, page-3

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 163 Posts.
    lightbulb Created with Sketch. 184
    re: Ann: AOD9604 Positive in Osteoarthritis A... Dear All,

    As in my previous posts, I am part of the CZD family due to Polynovo. AOD is now becoming interesting however.

    Very recent patents for osteoarthritis and at a stage ready for stage 2 clinical trials due to previous safety data... hence as long as a business partner can be found to share the risk and add in cash, AOD may yet make a considerable return on the >50million invested.

    ABC news today in their review of drugs in sport:

    "Growth hormone variants: The ACC report identified the use of Australian-owned growth hormone variant AOD-9604 in sport. The protein-based hormone helps burn fat and stimulates weight loss, though does not necessarily enhance muscle strength.Clinical trials have suggested it also helps repair muscle and tissue after strenuous activity.AOD-9604 is not prohibited by WADA."

    From this link:
    http://www.abc.net.au/news/2013-02-07/explainer-performance-enhancing-substances/4506126

    Hence, as I see it, this drug has the potential to be the first and currently only drug available worldwide to improve osteoarthritis (or arthritis primarily related to age and wear and tear, which if severe is really only treatable through major surgery and sawing out the joint to replace it)... damn exciting IF David Kenley is able to get a pharmaceutical partner to take it further.

    Congrats David Kenley on this progress.

    Good luck to all.

    Gav
 
watchlist Created with Sketch. Add CZD (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.